Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?
作者信息
Pichler Renate, Schmidinger Manuela
机构信息
Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S275. doi: 10.21037/atm.2019.11.138.
Abstract
摘要
相似文献
1
Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?免疫生物标志物能否预测转移性肾细胞癌患者从靶向药物中获益？
Ann Transl Med. 2019 Dec;7(Suppl 8):S275. doi: 10.21037/atm.2019.11.138.
2
Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience.转移性黑色素瘤和肾细胞癌中与高剂量白细胞介素-2反应相关的临床特征及治疗相关生物标志物：一所学术社区医院经验的回顾性分析
Springerplus. 2015 Mar 7;4:118. doi: 10.1186/s40064-015-0890-1. eCollection 2015.
3
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.血管内皮生长因子靶向治疗转移性肾细胞癌患者相关毒性治疗中止的风险因素和预测模型：来自国际转移性肾细胞癌数据库联盟的结果。
Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5.
4
Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.晚期肾细胞癌靶向治疗的给药策略与优化
J Oncol Pharm Pract. 2017 Jan;23(1):43-55. doi: 10.1177/1078155215618769. Epub 2016 Jul 9.
5
TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.塔里波试验：转移性肾细胞癌中靶向治疗联合或不联合肾切除术：用于生物标志物发现的液体活检
Tumori. 2018 Oct;104(5):401-405. doi: 10.5301/tj.5000699. Epub 2018 May 9.
6
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.细胞减灭性肾切除术治疗肾细胞癌同步转移患者：来自国际转移性肾细胞癌数据库联盟的结果。
Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.
7
Current status of prognostic factors in patients with metastatic renal cell carcinoma.转移性肾细胞癌患者预后因素的现状。
Int J Urol. 2019 Jun;26(6):608-617. doi: 10.1111/iju.13956. Epub 2019 Apr 8.
8
Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.在靶向治疗时代，分析术前变量以识别可能从转移性肾细胞癌先行细胞减灭性肾切除术中获益的患者。
Jpn J Clin Oncol. 2015 Jan;45(1):96-102. doi: 10.1093/jjco/hyu171. Epub 2014 Oct 23.
9
[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].[肾细胞癌分子靶向治疗反应的生物标志物]
Gan To Kagaku Ryoho. 2011 Jul;38(7):1088-91.
10
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.低钠血症对接受分子靶向治疗的转移性肾细胞癌患者生存的影响。
Int J Urol. 2012 Dec;19(12):1050-7. doi: 10.1111/j.1442-2042.2012.03115.x. Epub 2012 Aug 5.
本文引用的文献
1
Investigational MET inhibitors to treat Renal cell carcinoma.用于治疗肾细胞癌的研究性 MET 抑制剂。
Expert Opin Investig Drugs. 2019 Oct;28(10):851-860. doi: 10.1080/13543784.2019.1673366. Epub 2019 Oct 3.
2
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.帕博利珠单抗、依维莫司和舒尼替尼治疗转移性肾细胞癌患者的 PD-L1 表达与临床结局：METEOR 和 CABOSUN 随机临床试验分析。
Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1.
3
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
4
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
5
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma.肾细胞癌原发肿瘤和肺转移灶的免疫背景特征及异质性。
Immunotherapy. 2019 Jan;11(1):21-35. doi: 10.2217/imt-2018-0097.
6
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.2018 年转移性透明细胞肾细胞癌的系统治疗：当前范例、免疫治疗的应用及未来方向。
Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13.
7
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
8
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study.酪氨酸激酶抑制剂的体外和体内免疫调节作用研究。
Biol Blood Marrow Transplant. 2018 Feb;24(2):267-275. doi: 10.1016/j.bbmt.2017.10.039. Epub 2017 Nov 8.
9
Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.依赖受体酪氨酸激酶 c-MET 的反应性中性粒细胞反应限制了癌症免疫治疗。
Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.
10
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.卡博替尼对比舒尼替尼作为低危或中危转移性肾细胞癌患者的初始靶向治疗：联盟A031203 CABOSUN试验
J Clin Oncol. 2017 Feb 20;35(6):591-597. doi: 10.1200/JCO.2016.70.7398. Epub 2016 Nov 14.
Zotero 插件